Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 3, 2007, Pages 301-312

  Samimi, Goli ^a,b   Kishimoto, Shuichi ^a   Manorek, Gerald ^a   Breaux, James K ^a   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cisplatin; JM118; Satraplatin

Indexed keywords

CARBOPLATIN; CISPLATIN DERIVATIVE; COPPER 64; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; OXALIPLATIN; PACLITAXEL; PLATINUM; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; SATRAPLATIN;

ARTICLE; CARCINOMA CELL; CELL GROWTH; CELL ISOLATION; CELL SELECTION; CLONOGENIC ASSAY; CROSS RESISTANCE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DETOXIFICATION; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG ISOLATION; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CLONE CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 33845900696     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0271-0     Document Type: Article

References (45)

1. Andrews PA, Albright KD (1992) Mitochondrial defects in cis-diamminedichloroplatinum(Ii) resistant human ovarian carcinoma cells. Cancer Res 52:1895-1901
2. Andrews PA, Murphy MP, Howell SB (1985) Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res 45:6250-6253
3. Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, Capranico G, Animati F (2001) Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents 1:113-130
4. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193
5. Boulikas T, Vougiouka M (2003) Cisplatin and platinum drugs at the molecular level. Oncol Rep 10:1663-1682
6. Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB (2006) Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 11:1-12
7. Deng HB, Parekh HK, Chow KC, Simpkins H (2002) Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem 277:15035-15043
8. Fokkema E, Groen HJ, Helder MN, de Vries EG, Meijer C (2002) JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochem Pharmacol 63:1989-1996
9. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80
10. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, Howell SB (2004) The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66:817-823
11. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15
12. Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:14298-14302
13. Jennerwein M, Andrews PA (1995) Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II). Drug Metab Dispos 23:178-184
14. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo Y-M, Rochdi M, Howell S (2002) Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62:6559-6565
15. Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB (2003) The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 64:466-473
16. Katano K, Safaei R, Samimi G, Holzer A, Tomioka M, Goodman M, Howell SB (2004) Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin Cancer Res 10:4578-4588
17. Katsumata N (2003) Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer 89(Suppl 3):S9-S15
18. Kelland LR (2000) An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin Investig Drugs 9:1373-1382
19. Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, Harrap KR (1992) Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res 52:1710-1716
20. Komatsu M, Sumizawa T, Mutoh M, Chen Z-S, Terada K, Furukawa T, Yang X-L, Gao H, Miura N, Sugiyama T Akiyama S (2000) Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60:1312-1316
21. Lin X, Okuda T, Holzer A, Howell SB (2002) The copper transporter CTR1 regulates cisplatin uptake in saccharomyces cerevisiae. Mol Pharmacol 62:1154-1159
22. Malonne H, Atassi G (1997) DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs 8:811-822
23. Marverti G, Andrews PA (1996) Stimulation of cis- diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells. Clin Cancer Res 2:991-999
24. Metcalfe SA, Cain K, Hill BT (1986) Possible mechanisms for differences in sensitivity to cis-platinum in human prostate tumor cell lines. Cancer Lett 31:163-169
25. Miquel J (1993) (eds) CRC handbook of free radicals and antioxidants in biomedicine. CRC, Florida
26. Mishima M, Samimi G, Kondo A, Lin X, Howell SB (2002) The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 38:1405-1412
27. Muggia FM, Braly PS, Grady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18:106-115
28. Oldenburg J, Begg AC, van Vugt MJH, Ruevekamp M, Schornagel JH, Pinedo HM, Los G (1994) Characterization of resistance mechanisms to cis-diamminedichloroplatinum (II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Cancer Res 54:487-493
29. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200
30. Raynaud FI, Odell DE, Kelland LR (1996) Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels. Br J Cancer 74:380-386
31. Reardon JT, Vaisman A, Chaney SG, Sancar A (1999) Efficient nucleotide excision repair of cisplatinum, oxaliplatin, and bis-aceto-ammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59:3968-3971
32. Safaei R, Katano K, Larson BJ, Samimi G, Holzer AK, Naerdemann W, Tomioka M, Goodman M, Howell SB (2005) Intracellular localization and traYcking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin Cancer Res 11:756-767
33. Samimi G, Howell SB (2005) The effect of the copper transporters ATP7A and ATP7B on the cytotoxicity and cellular pharmacology of JM-118. Proc Am Assoc Cancer Res 46:969
34. Samimi G, Howell SB (2006) Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother Pharmacol 57:781-788
35. Samimi G, Katano K, Holzer AK, Safaei R, Howell SB (2004) Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 66:25-32
36. Samimi G, Manorek G, Castel R, Breaux JK, Cheng TC, Berry CC, Los G, Howell SB (2005) cDNA-microarray-based identification of genes and mechanisms associated with oxaliplatin resistance. Cancer Chemother Pharmacol 55:1-11
37. Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB (2004) Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10:4661-4669
38. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279
39. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, Van Erps P, Theodore C, Koriakine O, Oliver T, Lebwohl D, Debois M, Zurlo A, Collette L (2005) Phase III Trial of Satraplatin, an oral platinum plus Prednisone vs. Prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68:2-9
40. Tatibana M, Kita K, Taira M, Ishijima S, Sonoda T, Ishizuka T, Iizasa T, Ahmad I (1995) Mammalian phosphoribosylpyrophosphate synthetase. Adv Enzyme Regul 35:229-249
41. Teicher BA, Holden SA, Herman TS, Sotomayor EA, Khandekar V, Rosbe KW, Brann TW, Korbut TT, Frei E 3rd (1991) Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int J Cancer 47:252-260
42. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121
43. Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA (1992) Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 52:5674-5680
44. Wallner KE, DeGregorio MW, Li GC (1986) Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res 46:6242-6245
45. Waud WR (1987) Differential uptake of cis-diamminedichloro-platinum(II) in sensitive and resistant murine L1210 leukemia cell lines. Cancer Res 46:6549-6555